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Background. Previous studies examining protease inhibitor use in pregnancy and the rate of preterm and small-for-gestational-age
infants have yielded conflicting results. Methods. This was a retrospective study of HIV-infected women who delivered singleton
infants at our institution between 1984 and 2014.Womenwith protease inhibitor use were compared to women on regimens without
a protease inhibitor as well as those who received no antepartum antiretroviral therapy. Infants were considered preterm if less than
37 completed weeks of gestation and small-for-gestational-age if less than 10th percentile. Results. During the study period 1,004
pregnancies met inclusion criteria. Of those, 597 received a protease inhibitor as part of their regimen, 230 ART without a protease
inhibitor, and 177 no ART.There was no difference in the rate of preterm birth between groups who received ART with or without
a protease inhibitor, 14% versus 13%. There was no difference in the rate of small-for-gestational-age infants between the three
groups. Use of a protease inhibitor was associated with a greater fall in viral load during pregnancy, 𝑝 < 0.001. Conclusion. In this
population with access to prenatal care and ART, treatment with protease inhibitors was associated with a greater fall in viral load,
but not an increase in small or preterm infants.
1. Introduction
The rate of new HIV infections in the United States has
remained stable over recent years, with an annual infec-
tion rate in women of 9,500 cases [1]. Despite this, HIV
remains a significant public health concern, with 1.1 mil-
lion HIV-infected people currently living in the United
States. In addition, HIV-infected women are more frequently
becoming pregnant and present a unique challenge to clini-
cians. Antiretroviral therapy, recommended for all pregnant
women, serves two major functions. The first is treatment of
maternalHIV infection to prevent progression of disease.The
second is to provide chemoprophylaxis to prevent vertical
transmission to the fetus. Antiretroviral therapy decreases the
risk of vertical transmission through reduction of maternal
viral load as well as transplacental transfer of the drug
for preexposure prophylaxis. Guidelines published by the
National Institutes of Health (NIH) clearly state that all
pregnant women should receive combined antiretroviral
therapy regardless of disease status. However, selection of the
optimal treatment regimen is less straightforward [2].
Combination antiretroviral therapy, consisting of two
nucleoside reverse transcriptase inhibitors (NRTIs) plus
either a nonnucleoside reverse transcriptase inhibitor
(NNRTI) or a protease inhibitor, is recommended for all
HIV-infected pregnant women. The recommendations do
acknowledge that while there is associated risk, the benefits
of maternal treatment for both maternal and fetal health
outweigh these risks. Each class of antiretroviral drug has a
unique set of possible side effects. For example, NRTIs have
been associated with mitochondrial toxicity in rare individ-
uals, while nevirapine (a NNRTI) has been associated with
hepatotoxicity and rash, and efavirenz (also a NNRTI) has
been associated with fetal neural tube defects with early first
trimester exposure [2–6]. Protease inhibitor use in pregnancy
has been inconsistently associated with both preterm birth
and small-for-gestational-age infants, with a possible etiology
of decreased progesterone levels recently postulated [7–13].
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Table 1: Population characteristics in HIV-infected pregnant women by type of antepartum antiretroviral therapy.
ART with a protease inhibitor ART without a protease inhibitor No ART
𝑝 value
𝑛 = 597 𝑛 = 230 𝑛 = 177
Race/ethnicity 0.5
Black 413 (69) 154 (67) 114 (64)
Hispanic 112 (19) 43 (19) 33 (19)
White 68 (11) 33 (14) 28 (16)
Other 4 (1) 0 (0) 2 (1)
Nulliparity 183 (31) 75 (33) 79 (45) 0.005
Age at delivery, years 27.5 ± 5.9 25.7 ± 7.4 24.7 ± 6.3 <0.001
Gestational age at presentation
for prenatal care, weeks 12 [8, 21] 13.5 [9, 22] 23.5 [13, 34] <0.001
Data reported as mean ± SD, median [quartiles], or 𝑛 (%) as appropriate.
All possible effects of combination antiretroviral therapy
on the pregnancy must be taken into consideration when
counseling women with HIV infection and providing recom-
mendations for therapy. The objective of this study was to
determine whether protease inhibitor use in our population
is associated with preterm birth or small-for-gestational-age
infants. Our null hypothesis is that there is no difference in
the rate of preterm birth or small-for-gestational-age infants
in women receiving a protease inhibitor as part of their
prescribed treatment regimen.
2. Materials and Methods
Thiswas a retrospective cohort study of HIV-infected women
who delivered a singleton live born infant at our institution
from January 1984 through April 2014. This study was
approved by the Institutional Review Board of the Univer-
sity of Texas Southwestern Medical Center and Parkland
Hospital. All HIV-infected women who delivered at our
institution during the study period were identified and their
medical records were reviewed for demographic information,
markers of HIV disease status, class of antiretroviral therapy,
and delivery information.
Over the study period the treatment of HIV infection in
pregnancy evolved, and consequently the treatment provided
at our institution changed along with national treatment
guidelines. Prior to 1990 no therapy was available, followed
by a period of time when women received either single or
multiple nucleoside reverse transcriptase inhibitors. In 1997
combination ART with a protease inhibitor became first-
line at our institution and was usually well tolerated. There
were only two indications for a woman to be on an alternate
regimen: either she was well controlled at presentation for
prenatal care on an acceptable regimen, or she had a direct
contraindication to the preferred treatment regimen.
Womenwith a protease inhibitor as part of the prescribed
treatment regimen were compared to those on ART without
a protease inhibitor as well as to women who received no
antepartum ART. Demographic information and markers of
HIV disease status such as duration of diagnosis, CD4 cell
count, and HIV viral load were examined for association
with treatment received. Delivery outcomes including birth
weight and gestational age were then examined to evalu-
ate differences in the rate of preterm birth or small-for-
gestational-age infants. Infants were identified as premature
if born at less than 37 completed weeks of gestation and
small-for-gestational-age if they were less than the 10th
percentile for gestational age based upon an updated national
reference [14]. Logistic regression adjusting for ethnicity, age,
duration of diagnosis, CD4 count at initiation of prenatal
care and delivery, and HIV viral load at start of prenatal
care and delivery (as linear effects) was then performed.
Statistical analyses included Pearson chi-square, Student’s 𝑡-
test, Wilcoxon rank sum, and logistic regression, with 𝑝
values less than 0.05 considered significant. Analysis was
performed using SAS 9.2 (SAS Institute Inc., Cary, NC).
3. Results
During the study period 1,004 singleton live births were
delivered to 792 HIV-infected women who had medication
usage, gestational age at delivery, and birth weight available
for analysis. Of those pregnancies, 597 (59.5%) received a
protease inhibitor as part of their treatment regimen, 230
(22.9%) received ART without a protease inhibitor, and 177
(17.6%) received no antepartum ART. Of note, 144 of the 177
women who did not receive antepartum ART delivered their
infants after 1990, when ART was available at our institution.
These women were either diagnosed at the time of delivery,
or unable to demonstrate compliance with recommended
ART and therefore represent a fundamentally different group
of women. As shown in Table 1, ethnicity was not different
between the three groups. Women who did not receive
antepartum ART were more likely to be nulliparous than
women who received some form of therapy (𝑝 = 0.005),
while women who received a protease inhibitor were older
than those that did not (𝑝 < 0.001).When examining women
who received prenatal care, women who did not receive
antepartum ART presented later in gestation, a median of
23.5 weeks, compared towomenwho received treatment both
with or without a protease inhibitor, median of 12 and 13.5
weeks, respectively, 𝑝 < 0.001.
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Table 2: Markers of maternal disease status during pregnancy in HIV-infected women by type of antepartum antiretroviral therapy.
ART with a protease inhibitor ART without a protease inhibitor No ART
𝑝 value
𝑛 = 597 𝑛 = 230 𝑛 = 177
Duration of diagnosis, years 2.0 [0.5, 4.7] 1.0 [0.4, 2.7] 0.2 [0, 1.0] <0.001
Viral load, copies/mL
At presentation 2,054 [37, 20,965] 1,372 [0, 12,266] 4,770 [643, 20,400] 0.02
At delivery 0 [0, 251] 0 [0, 1347] 2,540 [0, 25,940] <0.001
CD4 count, cells/mm3
At presentation 463 [299, 626] 456 [314, 624] 557 [375, 747] 0.001
At delivery 524 [372, 693] 505 [349, 677] 565 [337, 717] 0.349
Data reported as median [quartiles].
When examining markers of maternal disease status, the
duration of diagnosis at delivery was significantly shorter,
a median of less than 3 months, for women who did not
receive antepartumART as compared to the other two groups
(Table 2). This is a result of the number of women who were
diagnosed at the time of delivery. Additionally, women who
received a protease inhibitor had been diagnosed with HIV
for a longer duration of time at presentation for prenatal care
than women who received ART without a protease inhibitor
(median 2.0 years versus 1.0 year, 𝑝 < 0.001).
HIV viral load and CD4 cell count at both presentation
for prenatal care and delivery were then examined. CD4 cell
count at presentation for prenatal care was higher in women
who did not receive ART when compared to those who
received some form of antepartum ART with a median of
557 cells/mm3 (𝑝 = 0.001) and did not change significantly
between presentation and delivery. In comparison, CD4 cell
counts at presentation for prenatal care for women receiving
antepartum ART both with and without a protease inhibitor
improved significantly over the duration of pregnancy but did
not differ between the groups with median values of 463 and
456 cells/mm3 at presentation and 524 and 505 cells/mm3 at
delivery, respectively. Viral load at presentation for prenatal
care was higher in women who did not receive antepartum
ART, median 4,770 copies/mL, compared to women who
received some form of antepartum ART. The median viral
load for women who received no ART fell slightly by the
time of delivery, median 2,540 copies/mL, despite a lack of
regular ART therapy in this group. Of note, when comparing
those women who received ART with and without a protease
inhibitor, viral load at presentation for prenatal care was
higher in women receiving a protease inhibitor, median
values of 2,054 and 1,372 copies/mL, respectively. However,
this discrepancy reversed by the time of delivery, as illustrated
in Figure 1, with viral load at delivery significantly lower in
women receiving a protease inhibitor, 𝑝 < 0.001.
There was a significant difference in gestational age at
delivery between the three groups as shown in Table 3, 𝑝 =
0.003, though the absolute difference was small. There was
no difference in the rate of premature birth between the two
groups of women who received ART with and without a
protease inhibitor, with rates of 14% and 13%, respectively.
However, women with no antepartum ART had a 21% rate
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Figure 1: Change in viral load during pregnancy for women
receiving ART with and without a protease inhibitor. Shaded area
represents one standard deviation from the mean, which is denoted
as the black line. Whiskers represent two standard deviations from
the mean. The change in log 10 viral load is significantly greater
for ART with a protease inhibitor (PI) using the Student-Newman-
Keuls test, 𝑝 < 0.001.
the other two groups, 𝑝 = 0.049. This trend continued with
examination of preterm birth less than 34 weeks of gestation,
with similar rates of 4 and 5% for the groups of women who
received ART with and without protease inhibitors and a
much higher rate of 10% for those womenwho did not receive
antepartum ART, 𝑝 = 0.01. When examining birth weight,
infants born to women who did not receive antepartum ART
weighed less, mean 2,904 grams, as compared to those infants
born to women receiving ART with and without a protease
inhibitor, mean of 3,080 and 3,010 grams, respectively, 𝑝 =
0.02. However, when adjusted for gestational age, the rate of
small-for-gestational-age infants did not differ between the
three groups.
Logistic regression was then performed to adjust for
ethnicity, maternal age, and duration of diagnosis, as well
as viral load and CD4 cell count at both presentation
for prenatal care and delivery as shown in Table 4. When
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Table 3: Selected pregnancy outcomes in HIV-infected women according to protease inhibitor use.
ART with a protease inhibitor ART without a protease inhibitor No ART
𝑝 value
𝑛 = 597 𝑛 = 230 𝑛 = 177
Gestational age at delivery, weeks 38.0 ± 2.3 38.5 ± 2.2 37.8 ± 3.0 0.003
Preterm birth <37 weeks 82 (14) 31 (13) 37 (21) 0.049∗
Preterm birth <34 weeks 26 (4) 11 (5) 18 (10) 0.01∗
Birth weight, grams 3010 ± 607 3080 ± 657 2904 ± 686 0.02
SGA 116 (19) 54 (23) 39 (22) 0.4
Data reported as mean ± SD, median (quartiles), or 𝑛 (%) as appropriate.
SGA: small-for-gestational-age defined as less than 10th percentile for gestational age.
∗
𝑝 values demonstrate a significance between women who did not receive ART and the other two groups.
Table 4: Unadjusted and adjusted odds ratios for pregnancy






Preterm birth <37 weeks
ART without protease inhibitor 1.0 (0.6, 1.5) 0.9 (0.5, 1.5)
No ART 1.7 (1.1, 2.6) 1.0 (0.5, 2.0)
SGA∗
ART without protease inhibitor 1.3 (0.9, 1.8) 1.3 (0.8, 1.9)
No ART 1.2 (0.8, 1.8) 1.1 (0.6, 2.0)
Logistic regression was performed to adjust for ethnicity, age, and duration
of diagnosis, as well as viral load and CD4 cell count at both presentation for
care and delivery.
Data reported as odds ratio (95% confidence interval) for women who
received the indicated therapy as compared to women receiving a protease
inhibitor.
∗SGA: small-for-gestational-age, defined as less than 10th percentile for
gestational age.
comparing women who received no antepartum ART to
those women who received ART with a protease inhibitor,
the unadjusted odds ratio for preterm birth was significantly
elevated at 1.7 with CI (1.1, 2.6); however the adjusted odds
ratio following regression analysis was 1.0. The odds ratio for
preterm birth both prior to and following regression analysis
was not different between the two groups of women who
received some form of ART. As previously shown in Table 3,
unadjusted risks for small-for-gestational-age infants did not
vary between the groups, which did not change following
logistic regression.
4. Discussion
In our population, use of protease inhibitors as part of
antiretroviral therapy in pregnancy was not associated with
preterm birth or small-for-gestational-age neonates. HIV
infection itself has been associated with both preterm birth
and low birth weight infants, though these rates have shown
some decrease over time [15]. Specifically, the national
preterm birth rate for the United States is approximately 12%
[16]; however the reported rate among HIV-infected women
is often higher, reported between 12 and 36% [7, 10, 11].
Therefore, while the rate of preterm birth in our study was
higher than the national rate for HIV-uninfected women, it
is comparable to the previously documented preterm birth
rates in HIV-infected women.
Importantly, though women with protease inhibitor use
in pregnancy presented to prenatal care with a higher
viral load than those women who received ART without
a protease inhibitor, by delivery this relationship reversed,
reflecting the ability of protease inhibitors to rapidly and
effectively minimize viral load. This may have direct clinical
implications. Currently, all women with a viral load greater
than 1,000 copies/mL at the time of delivery should be
offered cesarean delivery as well as intrapartum zidovudine
prophylaxis. In addition, maternal viral load at delivery is
inversely related to the risk of vertical transmission [2]. Use of
protease inhibitors in pregnancy may therefore decrease the
need for cesarean delivery and intrapartum zidovudine and
minimize vertical transmission to the infant. The data from
our study strengthens the recommendation for the inclusion
of protease inhibitors in the treatment regimen for HIV in
pregnancy as preterm birth and small-for-gestational age
infants were not increased with their use.
This is a large study of HIV-infected pregnant women
at a single institution who received care by a specialized
team of providers, a considerable strength. However, the
retrospective nature of this study, which was conducted over
a long study period, predisposes it to several confounding
variables. Unfortunately, themajority of studies reviewing the
risk of protease inhibitors have been retrospective, with only
randomized trial conducted in the setting of the developing
nation of Botswana [11]. In that study antiretroviral therapy
was initiated late in pregnancy (at 26–34 weeks of gestation),
and protease inhibitor use was associated with a preterm
birth rate of 21% compared to 12% of women receiving the
alternative regimen. In an attempt to control for the biases
introduced in a retrospective study, we included analyses to
control forHIVdisease status at presentation for prenatal care
and at delivery as well as ethnicity, and the results remained
unchanged. However, information on alcohol and tobacco
use and history of prior preterm birth was not available for
the entire cohort, all of which have been associated with
small-for-gestational-age infants and/or preterm birth [17–
19]. Despite these limitations, we are confident that in our
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population protease inhibitor therapy does not appear to be
associated with poor fetal growth or preterm birth.
Protease inhibitors are usually well tolerated in preg-
nancy and have been widely adopted for the treatment of
women with HIV both during and outside of pregnancy.
This study provides reassurance to clinicians that protease
inhibitors are not associated with preterm birth or small-for-
gestational-age infants in a population with early access to
antiretroviral therapy and regular prenatal care. At this time,
the optimal regimen for the treatment of pregnant women
with HIV infection in the United States is not clear, and
the NIH currently lists two treatment regimens as first-line
options: either a protease inhibitor or a NNRTI, plus two
NRTIs. Unfortunately, NNRTIs have been associated with
rapid development of resistance, limiting future treatment
options [20]. At this time, our study provides evidence of the
benefit of protease inhibitor use in pregnancy and provides
reassurance in regard to the risk of preterm birth or small-
for-gestational-age infants.
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